Table 1 Basic characteristics of the patient cohort with primary glioblastoma
From: Serum microRNA profiling in patients with glioblastoma: a survival analysis
Variables | Set one (N = 40) | Set two (N = 66) | Combined set (N = 106) |
|---|---|---|---|
Vital status | |||
Alive | 20 (50%) | 53 (84.1%) | 73 (68.9%) |
Dead | 20 (50%) | 13 (19.7%) | 33 (31.1%) |
Sex | |||
Female | 15 (37.5%) | 25 (37.9%) | 40 (37.7%) |
Male | 25(62.5%) | 41 (62.1%) | 66 (62.3%) |
Ethnicity | |||
White | 37 (92.5%) | 63 (95.4%) | 100 (94.3%) |
Non-White | 3 (7.5%) | 3 (4.54%) | 6 (5.7%) |
Smoking history | |||
Ever a smoker | 18 (45.0%) | 30 (45.5%) | 48 (45.3%) |
Never a smoker | 17 9(42.5%) | 29 (43.9%) | 46 (43.4%) |
Unknown | 5 (12.5%) | 5 (7.6%) | 10 (9.4%) |
Recurrence/progression | |||
Yes | 26 (65.0%) | 42 (63.6%) | 68 (64.8%) |
No | 14 (35.0%) | 23 (36.4%) | 37 (35.2%) |
KPS score | |||
100 | 8 (20.0%) | 15 (22.7%) | 23 (21.7%) |
90 | 20 (50.0%) | 27 (40.9%) | 47 (44.3%) |
80 | 5 (12.5%) | 14 (21.2%) | 19 (17.9%) |
< 80 | 7 (17.5%) | 10 (15.2%) | 17 (16.0%) |
Timing of blood draw | |||
Newly diagnosed, post surgery | 18 (45.0%) | 31 (47.0%) | 49 (46.2%) |
Newly diagnosed, immediately post or during radiation therapy | 0 (0.0%) | 3 (4.5%) | 3 (2.8%) |
Newly diagnosed, immediately post or during adjuvant chemotherapy | 12 (30.0%) | 14 (21.2%) | 26 (24.5%) |
Newly diagnosed, immediately post or during chemoradiation | 10 (25.0%) | 18 (27.3%) | 28 (26.4%) |
IDH1 mutation status | |||
Negative | 24 (60.0%) | 34 (51.5%) | 58 (54.7%) |
Positive | 3 (7.5%) | 6 (9.1%) | 9 (8.5%) |
unknown | 13 (32.5%) | 26 (39.4%) | 39 (36.8%) |
Age, mean (range) | 59 (45, 69) | 56 (46, 70) | 58 (45, 70) |
BMI, mean (range) | 28.5 (22.0, 35.4) | 27.4 (21.5, 36.1) | 28.1 (21.5, 36.1) |
Follow-up time, median (range) | 18 (2, 23) | 19 (3, 24) | 19 (2, 24) |